Adial Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $47.04K.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.22M.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $3.82M.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $58.00.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $4.81M, a 25.90% increase from fiscal 2024.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $3.82M, a 760191.05% increase from fiscal 2023.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $503.00, a 73.03% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.86K, a 99.60% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $4.81M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $47.04K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $2.22M 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $3.82M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $3.82M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $503.00 10-K · filed 2024-04-01 | |
| 2023-06-30 | $58.00 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $1.86K 10-K · filed 2024-04-01 | |
| 2021-12-31 | $469.50K 10-K · filed 2023-03-30 | |
| 2021-03-31 | $14.50K 10-Q · filed 2022-11-14 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | |
| 2019-03-31 | $1.17M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |